Mylan announced that it has launched Xulane (Norelgestromin/Ethinyl Estradiol Transdermal System) 150/35mcg per day, the generic version of Janssen’s Ortho Evra transdermal patch. Mylan received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for this product.
Ortho Evra is an estrogen/progestin combination hormonal contraceptive indicated for the prevention of pregnancy in women who elect to use a transdermal patch as a method of contraception. The primary mechanism of action is inhibition of ovulation, though it exerts additional changes to cervical mucus thickness and the endometrium which reduces the likelihood of implantation.
For more information, call (800) RX-MYLAN or visit mylan.com.